GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Urovant Sciences Ltd (NAS:UROV) » Definitions » Forward Rate of Return (Yacktman) %

Urovant Sciences (Urovant Sciences) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Urovant Sciences Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Urovant Sciences's forward rate of return for was 0.00%.

The historical rank and industry rank for Urovant Sciences's Forward Rate of Return (Yacktman) % or its related term are showing as below:

UROV's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 10.96
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Urovant Sciences Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Urovant Sciences's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Urovant Sciences Forward Rate of Return (Yacktman) % Chart

Urovant Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20
Forward Rate of Return (Yacktman) %
- - - -

Urovant Sciences Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Urovant Sciences's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Urovant Sciences's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Urovant Sciences's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Urovant Sciences's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Urovant Sciences's Forward Rate of Return (Yacktman) % falls into.



Urovant Sciences Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Urovant Sciences's Forward Rate of Return of Dec. 2020 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/16.13+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Urovant Sciences  (NAS:UROV) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Urovant Sciences Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Urovant Sciences's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Urovant Sciences (Urovant Sciences) Business Description

Industry
Traded in Other Exchanges
N/A
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Urovant Sciences Ltd is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's pipeline products include Overactive Bladder (OAB), OAB in Men with Benign Prostatic Hyperplasia (BPH), and IBS-Associated Pain.
Executives
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Sef Kurstjens director C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Walt Johnston officer: SVP, Commercial, USI UROVANT SCIENCES LTD. 5281 CALIFORNIA AVE SUITE 100 IRVINE CA 92617
Haag-molkenteller Cornelia officer: CMO/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617
Bryan E. Smith officer: GC/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Christine Ocampo officer: PAO;CAO/Urovant Sciences, Inc C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Ajay Bansal officer: PFO;CFO/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Robinson James A. Jr. director, officer: PEO;CEO/Urovant Sciences, Inc. 852 WINTER STREET, WALTHAM MA 02451
Sumitomo Chemical Co., Ltd. other: See Footnote (1) 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd other: See Footnote (1) 6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045
Keith Katkin director, officer: PEO;CEO/Urovant Sciences, Inc. C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Shigeyuki Nishinaka director 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617

Urovant Sciences (Urovant Sciences) Headlines

From GuruFocus

Urovant Sciences to Report Second Fiscal Quarter 2020 Financial Results

By Business Wire Business Wire 10-27-2020